Key points from Takeda Pharmaceutical Company’s (NYSE:TAK) presentation at JPMorgan’s Healthcare Conference:
12 new molecular entities (NMEs) in 14 indications to be launched over the next several years that are expected to generate more than $10B in sales.
14 global brands will drive sustainable growth.
About 40 NMEs in clinical development, 17 in Phase 2 or 3, eight potential best-in-class/first-in-class.
At least 15 product launches planned in China over the next five years.
About half the pipeline are Orphan Drugs.
On track to achieve target ot 2x net debt/non-GAAP EBITDA ratio and mid-30% core operating profit margin within the period of March 2022 – March 2024.
Divestitures should reach $10B.
Annual dividend of 180 yen to be maintained.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.